阿尔特苏纳酸通过降低瘤坏死因子-α诱导的HaCaT细胞中因特鲁金-23的表达来缓解牛皮类皮肤炎
Lixian Lin1, Zhongzhou Huang1, Ma Jianchi1
1Department of Dermatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Clinical and experimental pharmacology & physiology
|August 28, 2023
概括
抗疟疾药物阿特苏纳酸 (ART) 通过准皮肤细胞,有效治疗牛皮. 它降低了皮肤中的互白素-23 (IL-23) 表达,为这种炎症性皮肤疾病提供了一种新的治疗方法.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮是一种慢性炎症性皮肤疾病.
- 素-23 (IL-23) /素-17 (IL-17) 轴在牛皮病原发生过程中至关重要.
- 作为一种抗疟疾药物,阿尔特苏纳酸 (ART) 显示出免疫调节作用,并具有治疗牛皮的潜力.
研究的目的:
- 研究ART在治疗牛皮的机制.
- 为了确定皮肤是否是ART抗牛皮病作用的目标组织.
- 探索ART对牛皮中IL-23通路的影响.
主要方法:
- 在牛皮病变的IL-23表达的分析.
- 使用HaCaT细胞进行体外研究,以评估ART对IL-23表达和细胞行为的影响.
- 在体内实验中,使用一种因米奎莫德 (IMQ) 诱导的牛皮样小鼠模型进行实验.
主要成果:
- IL-23在牛皮病变的表皮表达很高,与疾病严重程度和中性粒细胞透有关.
- ART抑制了HaCaT细胞迁移,细胞循环和瘤坏死因子-α (TNF-α) 诱导的IL-23表达,可能通过核因子kappa B (NF-κB) 途径.
- 在小鼠牛皮病模型中,ART剂量依赖地降低了表皮IL-23并改善了中性粒细胞透.
结论:
- 皮肤可能是治疗牛皮的ART的目标组织.
- ART有效地降低了皮肤中的IL-23表达,这表明了一种新的治疗机制.
- 治疗牛皮的ART显示出作为治疗牛皮的有希望的治疗剂的潜力.
相关概念视频
T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
173
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
173
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Drugs for Treatment of Ulcerative Colitis in IBD
173
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
173


